Source link : https://newshealth.biz/health-news/trop2-drug-wins-two-new-indications-in-triple-negative-breast-cancer/
The FDA approved sacituzumab govitecan (Trodelvy) for two indications in patients with metastatic triple-negative breast cancer (TNBC). The first indication for the TROP2-targeting antibody-drug conjugate, supported by the ASCENT-03 trial, is for the first-line treatment of adults with unresectable locally advanced or metastatic disease who are not candidates for PD-1 or PD-L1 inhibitor-based therapy due […]
The post TROP2 Drug Wins Two New Indications in Triple-Negative Breast Cancer first appeared on News Health.
—-
Author : News Health
Publish date : 2026-06-25 14:29:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8